Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. (300452.SZ)
CNY12.79
+0.39 (+3.15%)
CN SHZ Healthcare Drug Manufacturers - Specialty & Generic
Address
Eco & Tech Dev Zn 232007
Huainan, CN
Huainan, CN
CEO
Dao Cai Song
Website
shanhe01.com
IPO
2015-05-15
ISIN CNE100001ZH5
Description
Headquartered in Huainan, China, Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. operates within China as a manufacturer and seller of pharmaceutical excipients and specialized medicines. The company's diverse offerings include cellulose, starch, povidone, stearic acid, coating powders, resins, and food additives. Furthermore, it exports these products internationally to regions such as Europe, the United States, and Southeast Asia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY12.79
+0.39 (+3.15%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
5M
Beta
0.21
Float Shares
217.99M
Free Float %
93.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.79% | -2.16% | -9.99% | -19.57% | -12.53% | -5.08% | -1.01% | -31.90% | +0.79% | -35.40% | +198.82% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
12.79
DCF (Unlevered)
41.93
+227.9%
DCF (Levered)
27.35
+113.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2025-08 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.85
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+6.8% ★ Q1'26: +5.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+43.1% ★ Q1'26: +0.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+16.3% ★ Q1'26: -0.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+22.5% ★ Q1'26: +22.1% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+32.5% ★ Q1'26: +32.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+3.3% Q1'26: -0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.19× ★ Q1'26: 1.43× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
258.92M
est: 287.00M (-9.8%)
|
286.40M
est: 320.00M (-10.5%)
|
339.36M
est: 404.00M (-16.0%)
|
428.56M
est: 517.00M (-17.1%)
|
531.20M
est: 534.71M (-0.7%)
|
616.71M
est: 658.39M (-6.3%)
|
705.00M
est.
|
839.26M
est: 843.50M (-0.5%)
|
704.53M
est: 843.50M (-16.5%)
|
882.57M
est: 854.00M (+3.3%)
|
942.80M
est: 981.50M (-3.9%)
|
1.03B
1.03B – 1.03B
+5.1% YoY
|
1.15B
1.15B – 1.15B
+11.1% YoY
|
1.28B
1.28B – 1.28B
+11.3% YoY
|
| EBITDA |
62.93M
est: 70.70M (-11.0%)
|
69.03M
est: 78.83M (-12.4%)
|
77.09M
est: 99.53M (-22.5%)
|
107.00M
est: 127.37M (-16.0%)
|
139.65M
est: 131.73M (+6.0%)
|
132.56M
est: 162.20M (-18.3%)
|
173.68M
est.
|
228.90M
est: 207.80M (+10.2%)
|
173.68M
est: 207.80M (-16.4%)
|
206.19M
est: 287.37M (-28.2%)
|
265.24M
est: 330.27M (-19.7%)
|
347.26M
347.26M – 347.26M
+5.1% YoY
|
385.96M
385.96M – 385.96M
+11.1% YoY
|
429.70M
429.70M – 429.70M
+11.3% YoY
|
| EBIT |
51.96M
est: 55.12M (-5.7%)
|
57.23M
est: 61.46M (-6.9%)
|
63.58M
est: 77.59M (-18.1%)
|
90.89M
est: 99.30M (-8.5%)
|
107.90M
est: 102.70M (+5.1%)
|
97.88M
est: 126.45M (-22.6%)
|
135.41M
est.
|
190.12M
est: 162.01M (+17.4%)
|
137.62M
est: 162.01M (-15.1%)
|
155.51M
est: 236.58M (-34.3%)
|
211.83M
est: 271.91M (-22.1%)
|
285.90M
285.90M – 285.90M
+5.1% YoY
|
317.75M
317.75M – 317.75M
+11.1% YoY
|
353.77M
353.77M – 353.77M
+11.3% YoY
|
| Net Income |
44.27M
est: 53.58M (-17.4%)
|
48.79M
est: 54.96M (-11.2%)
|
50.34M
est: 71.13M (-29.2%)
|
70.11M
est: 93.76M (-25.2%)
|
93.94M
est: 97.27M (-3.4%)
|
89.25M
est: 117.08M (-23.8%)
|
131.13M
est.
|
161.54M
est: 158.06M (+2.2%)
|
130.71M
est: 158.06M (-17.3%)
|
119.42M
est: 176.55M (-32.4%)
|
176.55M
est: 188.65M (-6.4%)
|
198.32M
198.32M – 198.32M
+5.1% YoY
|
224.92M
224.92M – 224.92M
+13.4% YoY
|
251.53M
251.53M – 251.53M
+11.8% YoY
|
| SGA |
42.77M
est: 11.43M (+274.1%)
|
44.57M
est: 12.75M (+249.7%)
|
42.95M
est: 16.09M (+166.9%)
|
54.69M
est: 20.60M (+165.5%)
|
43.64M
est: 21.30M (+104.9%)
|
52.05M
est: 26.23M (+98.5%)
|
28.08M
est.
|
60.00M
est: 33.60M (+78.6%)
|
51.13M
est: 33.60M (+52.2%)
|
63.54M
est: 54.61M (+16.3%)
|
18.18M
est: 62.77M (-71.0%)
|
66.00M
66.00M – 66.00M
+5.1% YoY
|
73.35M
73.35M – 73.35M
+11.1% YoY
|
81.66M
81.66M – 81.66M
+11.3% YoY
|
| EPS |
0.20
est: 0.23 (-12.6%)
|
0.21
est: 0.23 (-10.5%)
|
0.21
est: 0.30 (-30.9%)
|
0.30
est: 0.40 (-25.1%)
|
0.41
est: 0.42 (-1.3%)
|
0.38
est: 0.50 (-24.0%)
|
0.56
est.
|
0.69
est: 0.68 (+2.2%)
|
0.56
est: 0.68 (-17.0%)
|
0.51
est: 0.73 (-30.1%)
|
0.75
est: 0.78 (-3.8%)
|
0.82
0.82 – 0.82
+5.1% YoY
|
0.93
0.93 – 0.93
+13.4% YoY
|
1.04
1.04 – 1.04
+11.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
162.92M
OE per share TTM
0.67
Owner's Yield
5.45%
Maintenance CapEx ratio
16.90%
Maint CapEx / Avg PPE
57.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
198.9K
Shares Outstanding
234.46M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dao Cai Song | GM & Non-Independent Director | — | male |
| Hanfang Lei | Deputy GM & Director | — | female |
| Juan Ye | Accounting Supervisor | — | — |
| Qi Liu | Head of Finance & Secretary of the Board | — | male |
| Zihu Liu | Deputy General Manager | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300452.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
